Cardiometabolic disorders may represent endpoints of a unified pathophysiological continuum.
Stage-specific mediators serve as biomarkers for disease progression.
GLP-1 receptor agonists and SGLT2 inhibitors show benefits across multiple cardiometabolic conditions.
The shift from a multi-disease model to a UCD framework informs risk stratification and therapy.
Therapies targeting shared biological processes may improve outcomes across conditions.
Guideline-Based Recommendations
Diagnosis
Utilize biomarkers such as ceramides and TMAO for risk stratification.
Management
Consider pharmacologic modulation of the continuum with GLP-1 receptor agonists and SGLT2 inhibitors.
Monitoring & Follow-up
Monitor for progression of cardiometabolic disorders through shared risk factors.
Risks
High systolic blood pressure, dietary risks, elevated LDL cholesterol, high body mass index, and high fasting plasma glucose are significant modifiable risk factors.
Patient & Prescribing Data
Adults with overlapping cardiometabolic conditions.
Pharmacologic interventions should target the continuum rather than isolated endpoints.
Clinical Best Practices
Adopt a unified approach to managing cardiometabolic disorders.
Incorporate stage-specific biomarkers into clinical practice.
Utilize a multidisciplinary team for comprehensive patient management.
